American Journal of Cardiology
Volume 99, Issue 7 , Pages 903-905, 1 April 2007

Effects of Atorvastatin on Vitamin D Levels in Patients With Acute Ischemic Heart Disease

  • José L. Pérez-Castrillón, MD

      Affiliations

    • Internal Medicine Department, Río Hortega University Hospital, Faculty of Medicine of Valladolid, Valladolid, Spain
    • Corresponding Author InformationCorresponding author: Tel: 34-983-420-400; fax: 34-983-331-566.
  • ,
  • Gemma Vega, MD

      Affiliations

    • Internal Medicine Department, Río Hortega University Hospital, Faculty of Medicine of Valladolid, Valladolid, Spain
  • ,
  • Laura Abad, MD

      Affiliations

    • Internal Medicine Department, Río Hortega University Hospital, Faculty of Medicine of Valladolid, Valladolid, Spain
  • ,
  • Alberto Sanz, MD

      Affiliations

    • Pediatric Laboratory, Pediatrics-IBGM Department, Faculty of Medicine of Valladolid, Valladolid, Spain
  • ,
  • José Chaves, MD

      Affiliations

    • Pfizer, Madrid, Spain.
  • ,
  • Gonzalo Hernandez, MD

      Affiliations

    • Pfizer, Madrid, Spain.
  • ,
  • Antonio Dueñas, MD

      Affiliations

    • Internal Medicine Department, Río Hortega University Hospital, Faculty of Medicine of Valladolid, Valladolid, Spain

Received 20 September 2006; received in revised form 7 November 2006; accepted 7 November 2006.

Vitamin D deficiency is a risk factor for osteoporosis and other chronic diseases, including type 1 diabetes, hypertension, metabolic syndrome, and ischemic heart disease. Cholesterol and vitamin D share the 7-dehydrocolesterol metabolic pathway. This study evaluated the possible effect of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Eighty-three patients (52 men and 31 women) with an acute coronary syndrome (75 with acute myocardial infarction and 8 with unstable angina) were included. After diagnosis, patients received atorvastatin as secondary prevention. Serum vitamin D was measured by high-performance liquid chromatography at baseline and at 12 months. Atorvastatin treatment produced a statistically significant decrease in cholesterol and triglyceride levels and an increase in vitamin D levels (41 ± 19 vs 47 ± 19 nmol/L, p = 0.003). Vitamin D deficiency was decreased by 75% to 57% at 12 months. In conclusion, atorvastatin increases vitamin D levels. This increase could explain some of the beneficial effects of atorvastatin at the cardiovascular level that are unrelated to cholesterol levels.

 

 This study was supported by Pfizer, Madrid, Spain.

PII: S0002-9149(06)02488-X

doi:10.1016/j.amjcard.2006.11.036

American Journal of Cardiology
Volume 99, Issue 7 , Pages 903-905, 1 April 2007